Literature DB >> 16095504

Regional variations in peer reviewed liver allocation under the MELD system.

Hector Rodriguez-Luna1, Hugo E Vargas, Adyr Moss, Kunam S Reddy, Richard B Freeman, David Mulligan.   

Abstract

The Model for End-Stage Liver Disease (MELD) is used to assign priority for liver transplantation candidates. The Organ Procurement and Transplantation Network (OPTN) approved recognized exceptional diagnoses (RED's) for which MELD fails to accurately measure priority. Centers can request increased MELD points in cases not recognized by this policy (non-RED's). Our aim was to compare regional practices to justify non-RED requests for MELD adjustments. The UNOS/OPTN database was queried to extract all adult cases for which a non-RED MELD adjustment was requested from 2/27/02 until 8/27/03. The data were stratified by region and justification. Data for 29,510 listings were available. 26,947 had complete diagnosis information. There were 827 non-RED requests of which 477 (57.7%) petitions were approved by the regional review boards (RRBs). The approval rate varied significantly among regions (range: 28-75%, p<0.0001). The most common non-RED's were complications of portal hypertension (48%). The percentage of patients listed with non-RED's varied significantly among regions (0.7-8.3 %, p<0.0001), as did the proportion of patients transplanted with non-RED's (2.1-31.9%, p<0.0001). Demographics did not differ among regions requesting non-REDs.Widespread regional variations exist in the handling of requests for non-REDs. These variations point to the need for reform to standard exception criteria.

Entities:  

Mesh:

Year:  2005        PMID: 16095504     DOI: 10.1111/j.1600-6143.2005.01008.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  8 in total

1.  Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk.

Authors:  Ma Somsouk; Rachel Kornfield; Eric Vittinghoff; John M Inadomi; Scott W Biggins
Journal:  Liver Transpl       Date:  2011-02       Impact factor: 5.799

2.  MELD Exceptions and Rates of Waiting List Outcomes.

Authors:  A B Massie; B Caffo; S E Gentry; E C Hall; D A Axelrod; K L Lentine; M A Schnitzler; A Gheorghian; P R Salvalaggio; D L Segev
Journal:  Am J Transplant       Date:  2011-09-15       Impact factor: 8.086

3.  Orthotopic liver transplantation for giant liver haemangioma: A case report.

Authors:  Undine G Lange; Julian N Bucher; Markus B Schoenberg; Christian Benzing; Moritz Schmelzle; Tanja Gradistanac; Steffen Strocka; Hans-Michael Hau; Michael Bartels
Journal:  World J Transplant       Date:  2015-12-24

4.  Lack of standardization in exception points for patients with primary sclerosing cholangitis and bacterial cholangitis.

Authors:  D Goldberg; T Bittermann; G Makar
Journal:  Am J Transplant       Date:  2012-02-15       Impact factor: 8.086

5.  Variation in organ quality between liver transplant centers.

Authors:  M L Volk; H A Reichert; A S F Lok; R A Hayward
Journal:  Am J Transplant       Date:  2011-04-05       Impact factor: 8.086

6.  Model for End-Stage Liver Disease and liver cirrhosis-related complications.

Authors:  Luis Calzadilla Bertot; Eduardo Vilar Gomez; Linnet Alonso Almeida; Enrique Arus Soler; Luis Blanco Perez
Journal:  Hepatol Int       Date:  2012-10-10       Impact factor: 6.047

7.  United Network for Organ Sharing regional variations in appeal denial rates with non-standard Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exceptions: support for a national review board.

Authors:  Robert G Gish; Robert J Wong; Gordon Honerkamp-Smith; Ronghui Xu; Robert W Osorio
Journal:  Clin Transplant       Date:  2015-04-16       Impact factor: 2.863

8.  Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement.

Authors:  Andrew S Allegretti; Nathan E Frenk; Darrick K Li; Harish Seethapathy; Xavier F Vela Parada; Joshua Long; Paul Endres; Daniel S Pratt; Raymond T Chung; Suvranu Ganguli; Zubin Irani; Kei Yamada
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.